THERIVA BIOLOGICS INC (TOVX) Forecast, Price Target & Analyst Ratings
NYSEARCA:TOVX • US87164U5083
0.187 USD
0 (-1.37%)
At close: Mar 4, 2026
0.1869 USD
0 (-0.05%)
After Hours: 3/4/2026, 4:33:52 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for THERIVA BIOLOGICS INC (TOVX).
Forecast Snapshot
Consensus Price Target
$7.14
+ 3,718.18% Upside
Next Earnings Forecast
Release DateMar 4, 2026
PeriodQ4 / 2025
EPS Estimate-$0.44
Revenue Estimate
ChartMill Buy Consensus
80.00%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$7.14
Upside
+ 3,718.18%
From current price of $0.19 to mean target of $7.14, Based on 8 analyst forecasts
Low
$7.07
Median
$7.14
High
$7.35
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
8 analysts have analysed TOVX and the average price target is 7.14 USD. This implies a price increase of 3718.18% is expected in the next year compared to the current price of 0.187.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
TOVX was analyzed by 8 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about TOVX.
In the previous month the buy percentage consensus was at a similar level.
TOVX was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-05-08 | Maxim Group | Downgrade | Buy -> Hold |
| 2024-11-13 | Maxim Group | Maintains | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 4, 2026
PeriodQ4 / 2025
EPS Estimate-$0.44
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q86.55%
Number of Analysts4
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
TOVX is expected to report earnings on 3/4/2026. The consensus EPS estimate for the next earnings is -0.44 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A 110.11% | N/A 185.64% | N/A 94.37% | N/A 17.92% | N/A 20.66% | |||||||||||
| EBITDA YoY % growth | -40.91M | -39.09M 4.45% | -26M 33.49% | -17.3M 33.46% | -15.42M 10.87% | -9.96M 35.41% | -14.18M -42.37% | -21.29M -50.14% | -21.296M -0.03% | -19.29M 9.42% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -40.98M | -39.25M 4.22% | -26.25M 33.12% | -17.57M 33.07% | -15.66M 10.87% | -10.16M 35.12% | -14.27M -40.45% | -21.38M -49.82% | -21.431M -0.24% | -19.427M 9.35% | N/A 16.91% | N/A -42.58% | N/A -13.97% | N/A 36.18% | N/A 130.05% | N/A 1,600.00% | N/A 137.33% | N/A 20.87% | N/A 23.67% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | -4,375.00 | -2,537.50 42.00% | -1,487.50 41.38% | -749.96 49.58% | -232.50 69.00% | -152.50 34.41% | -52.50 65.57% | -31.75 39.52% | -29.25 7.87% | N/A 16.55% | N/A 84.58% | N/A 58.94% | N/A -3.30% | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.44 86.55% | -0.34 77.95% | -0.32 43.63% | -0.38 16.13% | -0.50 -12.64% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -4.378M 4.41% | -4.511M -2.14% | -5.654M 56.95% | -7.79M -69.69% | -10.734M -145.20% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
24.87%
EPS Next 5 Year
18.10%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
THERIVA BIOLOGICS INC / TOVX Forecast FAQ
What is the average price target for THERIVA BIOLOGICS INC (TOVX) stock?
8 analysts have analysed TOVX and the average price target is 7.14 USD. This implies a price increase of 3718.18% is expected in the next year compared to the current price of 0.187.
What is the next earnings date for TOVX stock?
THERIVA BIOLOGICS INC (TOVX) will report earnings on 2026-03-04, after the market close.
What are the consensus estimates for THERIVA BIOLOGICS INC (TOVX) next earnings?
The consensus EPS estimate for the next earnings of THERIVA BIOLOGICS INC (TOVX) is -0.44 USD and the consensus revenue estimate is 0 USD.